The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Phase 2b Trial Data on Treatment for Inflammation Due Soon
Source: Dr. Jonathan Aschoff (06/09/2025)

These results are expected to be favorable based on positive results of a recent interim study, noted a ROTH Capital Partners report.

Biotech Co. Reaches MS Clinical Program Milestones
Source: Jason Kolbert (06/09/2025)

These include release of additional Phase 2 trial data and completion of enrollment for two separate Phase 3 studies, noted a D. Boral Capital report.

Co.'s New Cancer Drug Shows Promise
Source: Jason Kolbert (06/09/2025)

Preclinical results support this asset's dual mechanism of action in abating cancer drug resistance and reversing cancer-induced immune suppression, noted a D. Boral Capital report.

Biotech Company Unlocks Gene Therapy Breakthrough in Canada
Source: Streetwise Reports (06/06/2025)

PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.

Healthcare Firm Uncovers AI Healthcare Growth Opportunity
Source: Streetwise Reports (06/06/2025)

Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) subsidiary Rocket Doctor was chosen by the Larta Institute to participate in its Bioscience and Healthcare Accelerator program. Read on to learn why one analyst says it is time to buy this company's stock.